The Latest Breaking News from Centene Corporation

The healthcare industry is expected to grow significantly, thanks to substantial demand driven by increasing health spending and an aging population worldwide. Moreover, because of the inelastic demand for healthcare solutions, the sector performs steadily regardless of the economic cycles. So, amid the current challenging environment, adding fundamentally sound healthcare…

Investors seem to show renewed interest in the healthcare sector as COVID-19 cases rise worldwide and portfolio resiliency amid the uncertain macro environment. So, fundamentally strong healthcare stocks Cigna Corp (CI), Centene Corp (CNC), and Humana (HUM) might be solid buys now. Read on.

Although Wall Street has been reeling under immense volatility due to persisting macroeconomic headwinds, it could be worth exploring buying opportunities in the stocks that provided the market some support with their solid performance. Centene (CNC), McKesson (MCK), and Enphase Energy (ENPH) have been among the market movers lately. So,…

Heavy insider buying can be a good indicator of future price appreciation for stocks because insiders often have insight into the growth prospects of their companies. Shares of Intel (INTC), CSX (CSX), Centene (CNC), and AutoZone (AZO) have been heavily bought by insiders of late. So, we think it could…

Persisting factors like the multi-decade high inflation, deepening supply chain constraints, and the expectation of a recession due to the Federal Reserve’s aggressive policy tightening could lead to a further market pullback. So, it could be wise to bet on fundamentally sound stocks Nutrien (NTR), Centene (CNC), Itochu (ITOCY), Steel…

Demand for health insurance policies has soared over the past couple of years and is projected to continue rising amid heightened health awareness in the post-pandemic era. Thus, we think the stocks of quality health insurance companies Humana (HUM), Cigna (CI), Centene (CNC), Molina Healthcare (MOH), and Anthem (ANTM) could…

Centene Corporation (NYSE:CNC) has agreed to sell Magellan Rx to Prime Therapeutics LLC and PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners.  Centene expects to receive approximately $2.8 billion in aggregate proceeds from the transactions. Magellan Rx is a comprehensive pharmacy solutions organization with specialty drug management, Medicaid administration, and comprehensive pharmacy…

Centene Corporation (NYSE:CNC) has reported a Q1 FY22 adjusted EPS of $1.83, compared to $1.63 a year ago, beating the consensus estimate of $1.68. Sales increased 24% Y/Y to $37.18 billion, beating the consensus of $34.50 billion. Health Benefits Ratio of 87.3%, up from 86.8% a year ago, due to a return…

Centene Corporation (NYSE: CNC) has reported Q4 adjusted EPS of $1.01,